Short answer
Xencor Inc (XNCR) filed an 8-K current report with the SEC on March 4, 2026 reporting Item 7.01 (Regulation FD Disclosure). Alexion (AstraZeneca sub) unilaterally stopped U.S. royalty payments on Ultomiris®, disputing obligation under existing license agreement.
Xencor Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Alexion (AstraZeneca sub) unilaterally stopped U.S. royalty payments on Ultomiris®, disputing obligation under existing license agreement
- At risk: $100–$120M in aggregate royalties Xencor expected to receive through 2028 on U.S. Ultomiris sales
- Alexion will continue paying ex-U.S. royalties, limiting but not eliminating ongoing royalty stream
- Xencor disputes Alexion's position and is "evaluating options": signals potential litigation over patent/license rights
- Cash guidance $380M–$400M by end of 2026, with runway into mid-2028, suggesting dispute doesn't threaten near-term solvency
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xencor Inc 8-K filings
Get the next XNCR 8-K as it lands
Follow XNCR for push alerts, or ask the research agent what this filing means.